ArticleCardiovascular diagnosis and therapy2025
Non-alcoholic fatty liver disease as a predictor of atrial fibrillation recurrence following ablation: a retrospective study.
Article in Cardiovascular diagnosis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Mechanism to Therapy: Establishing an Integrated Framework for the Regulation and Intervention of Matrix Vesicles in Vascular Calcification.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiological evidence suggests an association between non-alcoholic fatty liver disease (NAFLD) and incident atrial fibrillation (AF); however, the magnitude of this association and its prognostic value in predicting the recurrence of AF after radiofrequency catheter ablation (RFCA) have not been fully characterized. The present study was designed to elucidate the complex interplay between NAFLD and the risk of AF recurrence after ablation. Methods: A total of 1,182 patients with AF who underwent initial RFCA from June 2018 to December 2022 at the First Affiliated Hospital of Zhengzhou University were included in this retrospective cohort study. The Kaplan-Meier method was used to plot AF recurrence curves after ablation. Multivariable Cox models were then used to examine the associations between NAFLD and the recurrence of AF. Analyses were also conducted to assess whether the predictive effect of NAFLD was consistent across different subgroups. Results: Over a 1-year follow-up period, 30.1% of the patients experienced recurrent AF. The multivariable Cox analysis revealed that NAFLD was an independent risk factor for the recurrence of AF after controlling for model 2 (hazard ratio =1.37, 95% confidence interval: 1.10-1.70, P=0.005). These correlations remained statistically significant across various models. Further, incorporating NAFLD in the fully adjusted basic risk model significantly increased the ability of the model to predict AF recurrence, with the C-statistic increasing from 0.672 to 0.686 (P=0.03). Additionally, diabetes mellitus (DM) (P value for interaction =0.049) and female sex (P value for interaction =0.02) had a statistically significant interactive effect with NAFLD in predicting the recurrence of AF. Conclusions: NAFLD was found to be independently associated with the recurrence of AF after ablation. Moreover, the AF recurrence rate after RFCA was higher in the NAFLD patients who had DM or were female. The study showed that NAFLD may serve as a dependable marker for assessing AF recurrence risk in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.